These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 8376405)

  • 1. Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib.
    Rabinowitz I; Randi AM; Shindler KS; Tuley EA; Rustagi PK; Sadler JE
    J Biol Chem; 1993 Sep; 268(27):20497-501. PubMed ID: 8376405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expressed full-length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets.
    Kroner PA; Kluessendorf ML; Scott JP; Montgomery RR
    Blood; 1992 Apr; 79(8):2048-55. PubMed ID: 1373334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease.
    Ribba AS; Voorberg J; Meyer D; Pannekoek H; Pietu G
    J Biol Chem; 1992 Nov; 267(32):23209-15. PubMed ID: 1429668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.
    Rabinowitz I; Tuley EA; Mancuso DJ; Randi AM; Firkin BG; Howard MA; Sadler JE
    Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9846-9. PubMed ID: 1409710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin.
    Randi AM; Jorieux S; Tuley EA; Mazurier C; Sadler JE
    J Biol Chem; 1992 Oct; 267(29):21187-92. PubMed ID: 1400429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of type IIB von Willebrand disease mutation Arg(545)Cys on platelet glycoprotein Ib binding--studies with recombinant von Willebrand factor.
    Inbal A; Kornbrot N; Harrison P; Randi AM; Sadler JE
    Thromb Haemost; 1993 Dec; 70(6):1058-62. PubMed ID: 8165601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets.
    Mancuso DJ; Kroner PA; Christopherson PA; Vokac EA; Gill JC; Montgomery RR
    Blood; 1996 Oct; 88(7):2559-68. PubMed ID: 8839848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor.
    Ware J; Dent JA; Azuma H; Sugimoto M; Kyrle PA; Yoshioka A; Ruggeri ZM
    Proc Natl Acad Sci U S A; 1991 Apr; 88(7):2946-50. PubMed ID: 2011604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences.
    Randi AM; Rabinowitz I; Mancuso DJ; Mannucci PM; Sadler JE
    J Clin Invest; 1991 Apr; 87(4):1220-6. PubMed ID: 2010538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor.
    Matsushita T; Sadler JE
    J Biol Chem; 1995 Jun; 270(22):13406-14. PubMed ID: 7539426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the phenotypic abnormality of platelet-type von Willebrand disease in a recombinant glycoprotein Ib alpha fragment.
    Murata M; Russell SR; Ruggeri ZM; Ware J
    J Clin Invest; 1993 May; 91(5):2133-7. PubMed ID: 8486780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
    Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets.
    Cooney KA; Lyons SE; Ginsburg D
    Proc Natl Acad Sci U S A; 1992 Apr; 89(7):2869-72. PubMed ID: 1557393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
    Stepanian A; Ribba AS; Lavergne JM; Fressinaud E; Juhan-Vague I; Mazurier C; Girma JP; Meyer D
    Br J Haematol; 2003 Feb; 120(4):643-51. PubMed ID: 12588351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin.
    Berndt MC; Ward CM; Booth WJ; Castaldi PA; Mazurov AV; Andrews RK
    Biochemistry; 1992 Nov; 31(45):11144-51. PubMed ID: 1359905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor.
    Hilbert L; Jenkins PV; Gaucher C; Meriane E; Collins PW; Pasi KJ; Mazurier C
    Thromb Haemost; 2000 Aug; 84(2):188-94. PubMed ID: 10959688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor.
    Ribba AN; Hilbert L; Lavergne JM; Fressinaud E; Boyer-Neumann C; Ternisien C; Juhan-Vague I; Goudemand J; Girma J; Mazurier C; Meyer D
    Blood; 2001 Feb; 97(4):952-9. PubMed ID: 11159522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand disease.
    Ribba AS; Christophe O; Derlon A; Cherel G; Siguret V; Lavergne JM; Girma JP; Meyer D; Pietu G
    Blood; 1994 Feb; 83(3):833-41. PubMed ID: 8298143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leu 697-->Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease.
    Hilbert L; Gaucher C; de Romeuf C; Horellou MH; Vink T; Mazurier C
    Blood; 1994 Mar; 83(6):1542-50. PubMed ID: 8123843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.